These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15293848)

  • 21. New approaches to managing congestive heart failure.
    Gottlieb SS
    Curr Opin Cardiol; 1995 May; 10(3):282-7. PubMed ID: 7612978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
    LeJemtel TH
    Curr Cardiol Rep; 1999 May; 1(1):31. PubMed ID: 10980817
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M
    Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
    Matsui S; Matsumori A; Matoba Y; Uchida A; Sasayama S
    J Clin Invest; 1994 Sep; 94(3):1212-7. PubMed ID: 8083362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
    Ross JS; Goldfine SM; Herrold EM; Borer JS
    Am J Ther; 1998 Nov; 5(6):369-75. PubMed ID: 10099079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of vesnarinone on L-type single Ca2+ channel current in cultured ventricular myocytes of embryonic chick].
    Zhang Y; Li H; Lan T; Zeng X
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):403-7. PubMed ID: 8732061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful?
    Chatterjee K; Wolfe CL; DeMarco T
    Cardiol Clin; 1994 Feb; 12(1):63-72. PubMed ID: 8181026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of heart failure with preserved systolic function.
    de Groote P; Herpin D; Diévart F; Hanon O; Trochu JN; Artigou JY; Galinier M; Habib G; Juillière Y; Neuder Y; Roudaut R; Komajda M
    Arch Cardiovasc Dis; 2008 May; 101(5):361-72. PubMed ID: 18656095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on digoxin therapy in congestive heart failure.
    Haji SA; Movahed A
    Am Fam Physician; 2000 Jul; 62(2):409-16. PubMed ID: 10929703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
    Frye RF; Tammara B; Cowart TD; Bramer SL
    J Clin Pharmacol; 1999 Nov; 39(11):1177-83. PubMed ID: 10579149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimising the use of beta-blockers in older patients with heart failure.
    Owen A
    Drugs Aging; 2002; 19(9):671-84. PubMed ID: 12381236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of quinolinone derivative, vesnarinone, in combination with irradiation on human lung cancer cell lines.
    Fujita M; Tsuchida T; Fujita T; Higashino K
    Oncol Rep; 1999; 6(2):353-7. PubMed ID: 10023004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New medical therapies for advanced left ventricular dysfunction.
    Baughman K
    Cardiol Clin; 1995 Feb; 13(1):27-34. PubMed ID: 7796429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome.
    Takeuchi K; del Nido PJ; Ibrahim AE; Cao-Danh H; Friehs I; Glynn P; Poutias D; Cowan DB; McGowan FX
    J Thorac Cardiovasc Surg; 1999 Feb; 117(2):375-82. PubMed ID: 9918980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of apoptosis in human choriocarcinoma cell lines by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone).
    Isaka K; Fujito A; Sagawa Y; Yudate T; Nishi H; Ito H; Takayama M
    Oncol Rep; 2002; 9(6):1299-305. PubMed ID: 12375038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart failure secondary to left ventricular systolic dysfunction. Therapeutic advances and treatment recommendations.
    Dracup K
    Nurse Pract; 1996 Sep; 21(9):56-8, 61, 65-8. PubMed ID: 8884795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis.
    Fujiwara H; Arima N; Otsubo H; Matsushita K; Hidaka S; Arimura K; Kukita T; Yamaguchi K; Tanaka H
    Exp Hematol; 1997 Oct; 25(11):1180-6. PubMed ID: 9328455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vesnarinone for heart failure.
    Swedberg K; Wedel H
    N Engl J Med; 1994 Jan; 330(1):64; author reply 65. PubMed ID: 8259151
    [No Abstract]   [Full Text] [Related]  

  • 40. Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? A protagonist viewpoint.
    Williamson KM; Patterson JH
    Ann Pharmacother; 1997; 31(7-8):888-92. PubMed ID: 9220052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.